Abstract Treatment of tuberculosis (TB) involves the administration of anti-mycobacterial
drugs for several months. The emergence of drug-resistant strains of Mycobacterium …

Tuberculosis (TB) is an airborne infectious disease that kills almost two million individuals
every year. Multidrug‐resistant (MDR) TB is caused by strains of Mycobacterium …

Following infection with Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB), most human hosts are able to contain the infection and avoid progression to active TB …

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has co‐evolved with
the human immune system and utilizes multiple strategies to persist within infected cells, to …

Tuberculosis (TB) is a lethal disease and remains one of the top ten causes of mortality by
an infectious disease worldwide. It can also result in significant morbidity related to …

Treatment of tuberculosis (TB) remains challenging, with lengthy treatment durations and
complex drug regimens that are toxic and difficult to administer. Similar to the vast majority of …

Globally, more than 10 million people developed active tuberculosis (TB), with 1.4 million
deaths in 2020. In addition, the emergence of drug-resistant strains in many regions of the …

Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection.
Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment …

Highlights•TB is a nonresolving inflammatory disease.•Inflammatory mediators are
intertwined in networks during TB.•The pattern of infected cell death affects inflammation in …

Tuberculosis (TB) is the outcome of an insidious, protracted infection with Mycobacterium
tuberculosis (Mtb). It primarily affects the lung and is characterized by extensive focal …